Development of analytical method to detect a disease biomarker in horses
Adapting cutting edge technology
Based in Waterford, TriviumVet uses cutting-edge healthcare and pharmaceutical technologies to create clever, highly effective and functional products for the veterinary market.The TriviumVet pipeline comprises innovative treatments for diseases where there are no specific veterinary approved drugs. TriviumVet Diagnostics, a division of TriviumVet, is developing novel diagnostic tools with applications in both animal and human healthcare.
The company focuses on adapting cutting edge technology developed for human medicine to improve the accessibility for pets. Therapeutic candidates are formulated for species specific suitability, tested for safety and efficacy and are then submitted to the FDA (Centre for Veterinary Medicine) and the EMA European Medicines Agency (CVMP) for approval. The company has a product development pipeline targeting a range of canine, feline and equine conditions.
Innovation Voucher Programme
TriviumVet are developing a product to treat a debilitating condition in horses for which there is no approved treatment on the market. As part of this work, the company needed a sensitive analytical method which could detect and quantify a biomarker in blood samples. This task was made difficult by the low levels of the biomarker in the blood coupled with a range of interfering compounds and sample matrix components. The PMBRC Gateway developed a sample clean-up technique and demonstrated that the target biomarker could be quantified at low levels using ion chromatography.
1
Irish company
1
diagnostic aid
1
Innovation Voucher
“PMBRC helped us progress this project from a concept to a working diagnostic aid that can be used not only to progress our internal development work, but also to benefit veterinary patients in the field. Niall, Gautam and the wider PMBRC team went above and beyond our expectations to deliver on a challenging brief. We will certainly be working with this group again on other R&D projects in the future”
Stuart Fitzgerald
Head of Clinical Affairs, TriviumVet
TriviumVet & PMBRC Technology Gateway partnership
The success of the project allowed TriviumVet to proceed with clinical studies of their treatment which are currently underway.